Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer

Laura Orlando, Anna Cardillo, Andrea Rocca, Alessandra Balduzzi, Raffaella Ghisini, Giulia Peruzzotti, Aron Goldhirsch, Claudia D'Alessandro, Saverio Cinieri, Lorenzo Preda, Marco Colleoni

Research output: Contribution to journalArticle

Abstract

The clinical efficacy and antiangiogenic effect of low-dose, metronomic administration of cyclophosphamide (CTX) and methotrexate (MTX) (CM) have been demonstrated. The authors report results and long-term follow-up for patients with metastatic breast carcinoma who obtained prolonged clinical benefit with CM. Prospectively collected data from two successive clinical trials were evaluated. From July 1997 to October 2003, patients with metastatic breast carcinoma were treated with low-dose oral chemotherapy (MTX 2.5 mg, twice daily on day 1 and day 2 or 4, and CTX 50 mg daily). Patients who achieved prolonged clinical benefit for a duration of 12 months or more (complete remission, partial remission or stabilization of disease) were considered for the analysis. Median follow-up was 23 months. A total of 153 patients were enrolled and are evaluable: Eastern Cooperative Oncology Group performance status 0-1 in 90 patients, two or more sites of metastatic disease in 97 patients, zero regimen for metastatic breast carcinoma in 48 patients. Among 153 patients, five demonstrated complete remission and 25 partial remission. The proportion of patients who achieved prolonged clinical benefit was 15.7% (95% confidence interval 9.9-21.4%). Median time to progression for patients with prolonged clinical benefit was 21 months (range 12-37+ months). One patient maintained complete remission 42 months after therapy discontinuation. At the multivariate analysis endocrine responsiveness and the achievement of an objective response significantly correlated with the achievement of prolonged clinical benefit. Metronomic chemotherapy can induce prolonged clinical benefit in metastatic breast cancer, supporting its role as an additional therapeutic tool in the treatment of patients with metastatic breast carcinoma.

Original languageEnglish
Pages (from-to)961-967
Number of pages7
JournalAnti-Cancer Drugs
Volume17
Issue number8
DOIs
Publication statusPublished - Sep 2006

Fingerprint

Breast Neoplasms
Drug Therapy
Metronomic Administration
Methotrexate
Cyclophosphamide
Therapeutics
Multivariate Analysis
Clinical Trials
Confidence Intervals

Keywords

  • Angiogenesis
  • Breast cancer and prognosis
  • Metronomic chemotherapy

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research
  • Oncology

Cite this

Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. / Orlando, Laura; Cardillo, Anna; Rocca, Andrea; Balduzzi, Alessandra; Ghisini, Raffaella; Peruzzotti, Giulia; Goldhirsch, Aron; D'Alessandro, Claudia; Cinieri, Saverio; Preda, Lorenzo; Colleoni, Marco.

In: Anti-Cancer Drugs, Vol. 17, No. 8, 09.2006, p. 961-967.

Research output: Contribution to journalArticle

Orlando, Laura ; Cardillo, Anna ; Rocca, Andrea ; Balduzzi, Alessandra ; Ghisini, Raffaella ; Peruzzotti, Giulia ; Goldhirsch, Aron ; D'Alessandro, Claudia ; Cinieri, Saverio ; Preda, Lorenzo ; Colleoni, Marco. / Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. In: Anti-Cancer Drugs. 2006 ; Vol. 17, No. 8. pp. 961-967.
@article{8b87e2421638429a88c6ef0894e1c2b1,
title = "Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer",
abstract = "The clinical efficacy and antiangiogenic effect of low-dose, metronomic administration of cyclophosphamide (CTX) and methotrexate (MTX) (CM) have been demonstrated. The authors report results and long-term follow-up for patients with metastatic breast carcinoma who obtained prolonged clinical benefit with CM. Prospectively collected data from two successive clinical trials were evaluated. From July 1997 to October 2003, patients with metastatic breast carcinoma were treated with low-dose oral chemotherapy (MTX 2.5 mg, twice daily on day 1 and day 2 or 4, and CTX 50 mg daily). Patients who achieved prolonged clinical benefit for a duration of 12 months or more (complete remission, partial remission or stabilization of disease) were considered for the analysis. Median follow-up was 23 months. A total of 153 patients were enrolled and are evaluable: Eastern Cooperative Oncology Group performance status 0-1 in 90 patients, two or more sites of metastatic disease in 97 patients, zero regimen for metastatic breast carcinoma in 48 patients. Among 153 patients, five demonstrated complete remission and 25 partial remission. The proportion of patients who achieved prolonged clinical benefit was 15.7{\%} (95{\%} confidence interval 9.9-21.4{\%}). Median time to progression for patients with prolonged clinical benefit was 21 months (range 12-37+ months). One patient maintained complete remission 42 months after therapy discontinuation. At the multivariate analysis endocrine responsiveness and the achievement of an objective response significantly correlated with the achievement of prolonged clinical benefit. Metronomic chemotherapy can induce prolonged clinical benefit in metastatic breast cancer, supporting its role as an additional therapeutic tool in the treatment of patients with metastatic breast carcinoma.",
keywords = "Angiogenesis, Breast cancer and prognosis, Metronomic chemotherapy",
author = "Laura Orlando and Anna Cardillo and Andrea Rocca and Alessandra Balduzzi and Raffaella Ghisini and Giulia Peruzzotti and Aron Goldhirsch and Claudia D'Alessandro and Saverio Cinieri and Lorenzo Preda and Marco Colleoni",
year = "2006",
month = "9",
doi = "10.1097/01.cad.0000224454.46824.fc",
language = "English",
volume = "17",
pages = "961--967",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer

AU - Orlando, Laura

AU - Cardillo, Anna

AU - Rocca, Andrea

AU - Balduzzi, Alessandra

AU - Ghisini, Raffaella

AU - Peruzzotti, Giulia

AU - Goldhirsch, Aron

AU - D'Alessandro, Claudia

AU - Cinieri, Saverio

AU - Preda, Lorenzo

AU - Colleoni, Marco

PY - 2006/9

Y1 - 2006/9

N2 - The clinical efficacy and antiangiogenic effect of low-dose, metronomic administration of cyclophosphamide (CTX) and methotrexate (MTX) (CM) have been demonstrated. The authors report results and long-term follow-up for patients with metastatic breast carcinoma who obtained prolonged clinical benefit with CM. Prospectively collected data from two successive clinical trials were evaluated. From July 1997 to October 2003, patients with metastatic breast carcinoma were treated with low-dose oral chemotherapy (MTX 2.5 mg, twice daily on day 1 and day 2 or 4, and CTX 50 mg daily). Patients who achieved prolonged clinical benefit for a duration of 12 months or more (complete remission, partial remission or stabilization of disease) were considered for the analysis. Median follow-up was 23 months. A total of 153 patients were enrolled and are evaluable: Eastern Cooperative Oncology Group performance status 0-1 in 90 patients, two or more sites of metastatic disease in 97 patients, zero regimen for metastatic breast carcinoma in 48 patients. Among 153 patients, five demonstrated complete remission and 25 partial remission. The proportion of patients who achieved prolonged clinical benefit was 15.7% (95% confidence interval 9.9-21.4%). Median time to progression for patients with prolonged clinical benefit was 21 months (range 12-37+ months). One patient maintained complete remission 42 months after therapy discontinuation. At the multivariate analysis endocrine responsiveness and the achievement of an objective response significantly correlated with the achievement of prolonged clinical benefit. Metronomic chemotherapy can induce prolonged clinical benefit in metastatic breast cancer, supporting its role as an additional therapeutic tool in the treatment of patients with metastatic breast carcinoma.

AB - The clinical efficacy and antiangiogenic effect of low-dose, metronomic administration of cyclophosphamide (CTX) and methotrexate (MTX) (CM) have been demonstrated. The authors report results and long-term follow-up for patients with metastatic breast carcinoma who obtained prolonged clinical benefit with CM. Prospectively collected data from two successive clinical trials were evaluated. From July 1997 to October 2003, patients with metastatic breast carcinoma were treated with low-dose oral chemotherapy (MTX 2.5 mg, twice daily on day 1 and day 2 or 4, and CTX 50 mg daily). Patients who achieved prolonged clinical benefit for a duration of 12 months or more (complete remission, partial remission or stabilization of disease) were considered for the analysis. Median follow-up was 23 months. A total of 153 patients were enrolled and are evaluable: Eastern Cooperative Oncology Group performance status 0-1 in 90 patients, two or more sites of metastatic disease in 97 patients, zero regimen for metastatic breast carcinoma in 48 patients. Among 153 patients, five demonstrated complete remission and 25 partial remission. The proportion of patients who achieved prolonged clinical benefit was 15.7% (95% confidence interval 9.9-21.4%). Median time to progression for patients with prolonged clinical benefit was 21 months (range 12-37+ months). One patient maintained complete remission 42 months after therapy discontinuation. At the multivariate analysis endocrine responsiveness and the achievement of an objective response significantly correlated with the achievement of prolonged clinical benefit. Metronomic chemotherapy can induce prolonged clinical benefit in metastatic breast cancer, supporting its role as an additional therapeutic tool in the treatment of patients with metastatic breast carcinoma.

KW - Angiogenesis

KW - Breast cancer and prognosis

KW - Metronomic chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=33748463225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748463225&partnerID=8YFLogxK

U2 - 10.1097/01.cad.0000224454.46824.fc

DO - 10.1097/01.cad.0000224454.46824.fc

M3 - Article

C2 - 16940806

AN - SCOPUS:33748463225

VL - 17

SP - 961

EP - 967

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 8

ER -